ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
15. Juli 2024 07:00 ET
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
02. Juli 2024 07:00 ET
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for...
ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner
25. Juni 2024 07:00 ET
|
ANI Pharmaceuticals, Inc.
PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an...
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
24. Juni 2024 06:50 ET
|
ANI Pharmaceuticals, Inc.; Alimera Sciences, Inc.
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded...
ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference
29. Mai 2024 16:30 ET
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024...
ANI Pharmaceuticals Announces the Launch of Kionex® Suspension
20. Mai 2024 06:50 ET
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP)...
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance
10. Mai 2024 06:50 ET
|
ANI Pharmaceuticals, Inc.
Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of...
ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
01. Mai 2024 16:30 ET
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief...
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
18. April 2024 16:05 ET
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial...
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
09. April 2024 06:50 ET
|
ANI Pharmaceuticals, Inc.
BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the...